New Study: Platelet-Rich Plasma, Shockwave Therapy Show Therapeutic Efficacy in Interstitial Cystitis

Interstitial cystitis/bladder pain syndrome (IC/BPS) can be relentless: pelvic or bladder pain, urinary urgency, frequency, and the frustrating reality that many patients cycle through multiple therapies without durable relief.

A 2026 prospective pilot study published in Frontiers in Bioengineering and Biotechnology explored a regenerative approach that combines two modalities already used across medicine for tissue healing and inflammation modulation: low-intensity extracorporeal shockwave therapy (LI-ESWT) and platelet-rich plasma (PRP). The results are early, but compelling enough to pay attention to.

The study at a glance

Citation: Long C-Y, Chang C-Y, Sung I-C, Ke L-Y, Chuang H-Y (2026). Effect of combining low intensity-extracorporeal shockwave therapy with platelet-rich plasma among female patients with interstitial cystitis: a prospective single-arm pilot study. Front. Bioeng. Biotechnol. 14:1801578. https://doi.org/10.3389/fbioe.2026.1801578

Design: Prospective, single-arm exploratory pilot study (no control group)

Participants: 25 female patients with IC/BPS

Protocol (as reported):

• LI-ESWT once weekly for 8 weeks (20–30 minutes/session; applied above the pubic bone)

• High-dose PRP injections administered in weeks 1, 5, and 9

Follow-up: Baseline, 1 month post-treatment, and 6 months post-treatment

Safety: No severe side effects reported

What improved (and when)

The authors reported an 80% success rate at 6 months using a patient-reported Global Response Assessment (GRA) threshold of “moderately” or “markedly” improved.

They also observed improvements across multiple symptom and quality-of-life measures.

Short-term (1 month) improvements were strongest

At the 1-month follow-up, the study reported statistically significant improvements in:

• Pain (VAS): from 5.4 ± 2.3 to 1.6 ± 1.7

• Overactive bladder symptoms (OABSS): from 6.1 ± 3.6 to 3.9 ± 2.8

• Urinary distress (UDI-6): from 42.9 ± 17.0 to 29.4 ± 11.0

• Incontinence impact (IIQ-7): from 79.6 ± 15.2 to 47.6 ± 32.5

• Pelvic organ prolapse distress (POPDI-6): from 11.4 ± 5.0 to 5.6 ± 3.5

Voiding diary measures also improved at 1 month, including fewer urinations per day and increased voided volume.

By 6 months, some measures regressed, but key IC scores stayed improved

At 6 months, several general urinary symptom and quality-of-life scores trended back toward baseline. However, the study still reported significant improvements in:

• ICSI (Interstitial Cystitis Symptom Index): from 12.0 ± 3.7 to 4.9 ± 3.8

• ICPI (Interstitial Cystitis Problem Index): from 10.8 ± 4.1 to 3.8 ± 1.5

• OSS (O’Leary–Sant Symptom Score): from 24.8 ± 7.7 to 8.7 ± 4.3

On the urodynamics side, the study reported a statistically significant increase in:

• MCC (Maximum Cystometric Capacity): from 261.4 ± 75.9 mL to 341.6 ± 38.0 mL

The authors interpreted this as a potentially meaningful functional improvement in bladder storage capacity and hypersensitivity.

Why combine PRP and shockwave?

The rationale is a “1 + 1 = 3” hypothesis:

• PRP delivers a concentrated mix of growth factors (e.g., PDGF, TGF-β, IGF-1) that may support tissue repair and remodeling.

• Low-intensity shockwave is believed to stimulate mechanotransduction pathways that can influence angiogenesis, inflammation modulation, and tissue remodeling.

The authors propose that shockwave may also help enhance the distribution and bioavailability of PRP-derived factors, potentially expanding the effective treatment area.

The most important caveat: promising, but early

This was a small, single-arm pilot study without a placebo or comparison group. That matters.

IC/BPS symptoms can fluctuate, and patient-reported outcomes can be influenced by expectation effects, regression to the mean, and natural disease variability.

Where HyperWave fits in: the same shockwave technology category

HyperWave’s branded focused shockwave is built on the same core category of therapeutic shockwave technology used across regenerative medicine: noninvasive acoustic waves applied to targeted tissue to stimulate biological responses.

In other words: while protocols and indications vary, the study reinforces a broader clinical theme—shockwave is being actively investigated and used as a regenerative tool in urology and pelvic health, not just orthopedics.

Bottom line

IC/BPS is complex and notoriously difficult to treat. This early research suggests that shockwave-based regenerative strategies—especially when paired with biologics like PRP—may offer meaningful symptom improvement for some patients, with the important note that durability may require ongoing care.

References

1. Long C-Y, Chang C-Y, Sung I-C, Ke L-Y, Chuang H-Y (2026). Effect of combining low intensity-extracorporeal shockwave therapy with platelet-rich plasma among female patients with interstitial cystitis: a prospective single-arm pilot study. Front. Bioeng. Biotechnol. 14:1801578. https://doi.org/10.3389/fbioe.2026.1801578

Medical disclaimer: This article is for educational purposes and does not constitute medical advice. Treatment decisions should be made by qualified clinicians based on individual patient evaluation.